Research and development organization focusing on the development, acquisition, and commercialization of specialty pharmaceuticals. The company's Hydron(tm) implant technology is in Phase III clinical trials as a treatment for prostate cancer. The bulk of revenue is derived from activity in the biotechnology industry. Products include prostate cancer treatment implant research and development - Hydrom(tm), prostate anticancer systems.